TR199701647A2 - Ikame edilmis purin türevleri,bunlarin imalat usulü - Google Patents

Ikame edilmis purin türevleri,bunlarin imalat usulü

Info

Publication number
TR199701647A2
TR199701647A2 TR97/01647A TR9701647A TR199701647A2 TR 199701647 A2 TR199701647 A2 TR 199701647A2 TR 97/01647 A TR97/01647 A TR 97/01647A TR 9701647 A TR9701647 A TR 9701647A TR 199701647 A2 TR199701647 A2 TR 199701647A2
Authority
TR
Turkey
Prior art keywords
revleri
imalat
edilmi
bunlar
usul
Prior art date
Application number
TR97/01647A
Other languages
English (en)
Other versions
TR199701647A3 (tr
Inventor
Peyman Dr.Anuschirwan
Knolle Dr.Jochen
Wehner Dr.Volkmar
Breipohl Dr.Gerhard
Gourvest Dr.Jean-Franco�S
Carniato Dr.Denis
Richard Gadek Dr.Thomas
Original Assignee
Hoechst Aktiengesellschaft
Genentech,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft, Genentech,Inc. filed Critical Hoechst Aktiengesellschaft
Publication of TR199701647A3 publication Critical patent/TR199701647A3/tr
Publication of TR199701647A2 publication Critical patent/TR199701647A2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut bulusun konusu formül I ve Ia'ya göre olan bilesikler, ki formülde X,Y,W,W,G, ve G istemlere belirtilen anlamlara sahiptirler,bunlarin fizyolojik olarak tahammül edilebilir tuzlari ve bunlarin ilaç sekilleri,bunlarin imal edilmesi, bunlarin özellikle ilaç maddesi olarak kullanimi ve bunlari ihtiva eden ispençiyari müstahzarlaridir.Formül I'e göre olan bilesikler vitronektin reseptör antagonistleri olup örnek olarak kemik resorpsiyonunun inhibitörleri olarak ve kemik erimesinin tedavisi için kullanilabilmektedir
TR97/01647A 1996-12-20 1997-12-18 Ikame edilmis purin türevleri,bunlarin imalat usulü TR199701647A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (2)

Publication Number Publication Date
TR199701647A3 TR199701647A3 (tr) 1998-07-21
TR199701647A2 true TR199701647A2 (tr) 1998-07-21

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01647A TR199701647A2 (tr) 1996-12-20 1997-12-18 Ikame edilmis purin türevleri,bunlarin imalat usulü

Country Status (22)

Country Link
EP (1) EP0853084B1 (tr)
JP (1) JP4620190B2 (tr)
KR (1) KR19980064655A (tr)
CN (2) CN1495184A (tr)
AR (1) AR010700A1 (tr)
AT (1) ATE404562T1 (tr)
AU (1) AU728865B2 (tr)
BR (1) BR9706387A (tr)
CA (1) CA2225366C (tr)
CZ (1) CZ294437B6 (tr)
DE (2) DE19653646A1 (tr)
HK (1) HK1012190A1 (tr)
HU (1) HUP9702507A3 (tr)
ID (1) ID19254A (tr)
IL (1) IL122642A0 (tr)
NO (1) NO314583B1 (tr)
NZ (1) NZ329431A (tr)
PL (1) PL323969A1 (tr)
RU (1) RU2228335C2 (tr)
TR (1) TR199701647A2 (tr)
TW (1) TW523515B (tr)
ZA (1) ZA9711317B (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052872A1 (fr) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. DERIVES D'AMINOPIPERIDINE COMME ANTAGONISTES D'INTEGRINE αvβ¿3?
KR20010109275A (ko) 1998-12-23 2001-12-08 로저 에이. 윌리암스 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
EP1176145A1 (en) 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
PL363311A1 (en) 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
ES2540733T3 (es) 2007-10-11 2015-07-13 Daiichi Sankyo Company, Limited Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
WO2009065035A1 (en) * 2007-11-14 2009-05-22 Myriad Genetics, Inc. Therapeutic compounds and their use in treating diseases and disorders
JP5653909B2 (ja) 2009-04-09 2015-01-14 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
RU2014143798A (ru) 2012-03-30 2016-05-27 Дайити Санкио Компани, Лимитед Антитело к сиглек-15 с модифицированной cdr
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (tr) * 1966-12-10 1972-09-13
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
WO1996020212A2 (en) * 1994-12-28 1996-07-04 Buchardt, Dorte Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JP2001518054A (ja) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ，インコーポレーテッド Ｐｎａ−ｄｎａキメラと、このキメラ合成用のｐｎａシントン
AU725254B2 (en) * 1996-03-26 2000-10-12 Du Pont Pharmaceuticals Company Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
CA2261566A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
BR9706387A (pt) 2000-03-14
CN1495184A (zh) 2004-05-12
CN1101816C (zh) 2003-02-19
RU2228335C2 (ru) 2004-05-10
JP4620190B2 (ja) 2011-01-26
EP0853084A3 (de) 1998-09-09
PL323969A1 (en) 1998-06-22
NO975977L (no) 1998-06-22
EP0853084A2 (de) 1998-07-15
ZA9711317B (en) 1998-06-22
HU9702507D0 (en) 1998-03-02
MX9710277A (es) 1998-10-31
ID19254A (id) 1998-06-28
DE59712958D1 (de) 2008-09-25
CA2225366C (en) 2006-10-10
HK1012190A1 (en) 1999-07-30
AR010700A1 (es) 2000-06-28
CZ294437B6 (cs) 2005-01-12
CZ411497A3 (cs) 1998-07-15
IL122642A0 (en) 1998-08-16
HUP9702507A2 (hu) 1999-05-28
ATE404562T1 (de) 2008-08-15
NZ329431A (en) 2000-01-28
AU728865B2 (en) 2001-01-18
JPH10182645A (ja) 1998-07-07
CA2225366A1 (en) 1998-06-20
TW523515B (en) 2003-03-11
TR199701647A3 (tr) 1998-07-21
NO975977D0 (no) 1997-12-19
AU4846697A (en) 1998-06-25
CN1193623A (zh) 1998-09-23
EP0853084B1 (de) 2008-08-13
HUP9702507A3 (en) 1999-12-28
KR19980064655A (ko) 1998-10-07
NO314583B1 (no) 2003-04-14
DE19653646A1 (de) 1998-06-25

Similar Documents

Publication Publication Date Title
TR199701647A2 (tr) Ikame edilmis purin türevleri,bunlarin imalat usulü
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
ATE316083T1 (de) Adamantanderivate
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
SE9902987D0 (sv) Novel compounds
SE9904505D0 (sv) Novel compounds
JO2371B1 (en) 4-phenyl-pyridine derivatives
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
TR199802344A2 (tr) Ikame edilmis imidazolidin türevleri
TR199701645A2 (tr) Vitronektin reseptör antagonistleri,bunlarin imalati ve kullanimi
DK0738269T3 (da) Piperidinderivater med PAF-antagonistaktivitet
DE60001586D1 (de) Diphenyl-piperidin derivate
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
DE69819539D1 (de) Antithrombotische mittel
SE9902551D0 (sv) Novel compounds
CY1106396T1 (el) Γραμμικες ή κυκλικες ουριες, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τις πepιεχουν
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
DK0552765T3 (da) benzimidazoler, farmaceutiske præparater indeholdende disse og fremgangsmåde til deres fremstilling